Barr Pharmaceuticals said a court backed its patent challenge of Mirapex, Boehringer Ingelheim's treatment for restless leg syndrome; Barr got FDA approval for a generic version in February. Mirapex sales came to $381 million for the 12 months ended in April, IMS Health figures show. Report